¶ Neuroinflammation in Alzheimer's and Parkinson's Disease
Neuroinflammation is a fundamental pathological hallmark of neurodegenerative diseases, characterized by chronic activation of glial cells (microglia and astrocytes) and sustained elevation of pro-inflammatory mediators in the central nervous system. While acute neuroinflammation serves as a protective response to injury or infection, the transition to chronic neuroinflammation becomes maladaptive and contributes significantly to neuronal death, synaptic loss, and disease progression in both Alzheimer's disease (AD) and Parkinson's disease (PD)heneka2015 2015, heneka2015glass2010 2010, glass2010.
The past decade has witnessed a paradigm shift in our understanding of neuroinflammation, moving from the view of it as a secondary phenomenon to recognition of its central role in disease initiation and propagation. Microglia, the resident immune cells of the brain, have emerged as critical players in neurodegeneration, with genome-wide association studies (GWAS) identifying multiple microglial genes as risk factors for AD and PDdeczkowska2021 2021, deczkowska2021.
Neuroinflammation encompasses a complex cascade of cellular and molecular events involving the activation of microglia, astrocytes, endothelial cells, and peripheral immune cells. This inflammatory response is mediated by a network of cytokines, chemokines, reactive oxygen species (ROS), and signaling pathways that, when dysregulated, create a neurotoxic environmentglass2010 2010, glass2010.
In Alzheimer's disease, neuroinflammation is intimately linked to the two core pathological hallmarks: amyloid-beta (Aβ) plaques and tau neurofibrillary tangles. Microglial cells cluster around amyloid plaques in characteristic patterns, and evidence suggests that chronic microglial activation may precede detectable amyloid deposition in some caseslambert2013 2013, lambert2013. Similarly, in Parkinson's disease, neuroinflammation accompanies alpha-synuclein aggregation and dopaminergic neuron loss in the substantia nigra pars compacta (SNc), with post-mortem studies consistently demonstrating elevated inflammatory markers in affected brain regionshirsch2009 2009, Neuroinflammation in Parkinson.
Cytokines are small signaling proteins that mediate cell-to-cell communication during inflammation. In neurodegeneration, pro-inflammatory cytokines create a self-perpetuating cycle of glial activation and neuronal damageheneka2015 2015, heneka2015cunningham2013 2013, cunningham2013.
| Cytokine |
Primary Source |
Role in Neurodegeneration |
Clinical Relevance |
| IL-1β |
Microglia, astrocytes |
Promotes tau phosphorylation and aggregation; induces synaptic dysfunction; enhances Aβ production |
Elevated in AD and PD CSF; associated with disease severity |
| IL-6 |
Glial cells, neurons |
Neurotoxic effects; impairs adult neurogenesis; disrupts synaptic plasticity |
Serum IL-6 predicts cognitive decline in AD |
| TNF-α |
Microglia, astrocytes |
Induces neuronal apoptosis; disrupts blood-brain barrier (BBB); amplifies neuroinflammation |
Anti-TNF therapies in clinical trials for AD/PD |
| IL-18 |
Microglia |
Pro-inflammatory; activates caspase-1 and the NLRP3 inflammasome; promotes tau pathology |
Elevated in AD and PD brainsmaphis2015 2015, maphis2015 |
| IFN-γ |
T cells, NK cells |
Promotes microglial activation; contributes to synaptic loss |
Associated with faster disease progression |
Chemokines are small cytokines that direct immune cell migration and positioning. They play crucial roles in recruiting peripheral immune cells to the brain and regulating microglial surveillance behaviorransohoff2014 2014, Chemokines and chemokine receptors: standing at the crossroads of immunobiolo....
- CCL2 (MCP-1): Chemoattractant for monocytes and microglia; elevated in AD and PD brains; promotes neuroinflammation
- CXCL12 (SDF-1): Regulates microglial migration and process motility; implicated in Aβ-induced neurotoxicity
- CX3CL1 (Fractalkine): Membrane-bound and soluble forms mediate neuron-microglia communication; CX3CR1 deficiency enhances neuroinflammation in mouse models
- CXCL10 (IP-10): Induced by IFN-γ; elevated in AD and PD brains; attracts T cells to the CNS
- CCL5 (RANTES): Pro-inflammatory chemokine; elevated in AD and PD cerebrospinal fluid (CSF)
Multiple signaling pathways coordinate the neuroinflammatory response and represent attractive therapeutic targetsliu2017 2017, liu2017.
- NF-κB pathway: Master regulator of inflammatory gene expression; activated by Aβ, tau, and alpha-synuclein; induces transcription of cytokines, chemokines, and adhesion molecules
- MAPK pathways: p38, JNK, and ERK signaling mediate stress-induced inflammation; p38 inhibitors in clinical development
- JAK-STAT pathway: Cytokine signaling cascade; STAT1 and STAT3 activation in glia; associated with neurotoxic phenotype
- NLRP3 inflammasome: Cytoplasmic complex that activates caspase-1 and processes pro-IL-1β and pro-IL-18; activated by Aβ and alpha-synuclein; genetic variants increase AD risk
- TREM2 signaling: Triggering receptor expressed on myeloid cells 2; regulates microglial phagocytosis, survival, and inflammatory response; AD risk variants impair microglial function
Microglia exist in a spectrum of activation states, transitioning from homeostatic surveillance to disease-associated phenotypes. Single-cell RNA sequencing has revealed remarkable heterogeneity in microglial states across brain regions and disease stagesdeczkowska2021 2021, deczkowska2021kerenshaul2017 2017, kerenshaul2017.
Homeostatic microglia survey the brain parenchyma, extending and retracting processes every few minutes. They express low levels of inflammatory genes and high levels of genes involved in phagocytosis (e.g., TREM2, CD33).
Disease-associated microglia (DAM) upregulate a distinct gene program including APOE, TREM2, and genes involved in lipid metabolism. DAM cluster around amyloid plaques in a TREM2-dependent manner and may play both protective (Aβ clearance) and harmful (pro-inflammatory) roles.
Neurodegenerative microglia (MGnD) represent a pro-inflammatory, neurotoxic phenotype characterized by high expression of inflammatory genes (IL1B, TNF, CCL2) and reduced phagocytic capacity.
- Amyloid plaques as inflammatory foci: Aβ fibrils activate microglia via multiple receptors (TLR2, TLR4, CD36, RAGE), triggering NF-κB activation and cytokine productionlambert2013 2013, lambert2013
- Tau pathology amplifies inflammation: Hyperphosphorylated tau activates microglia through the NLRP3 inflammasome; neurofibrillary tangle burden correlates with microglial activationmaphis2015 2015, maphis2015hoeijmakers2022 2022, hoeijmakers2022
- APOE4 enhances neuroinflammation: APOE4 carriers show increased microglial activation and pro-inflammatory cytokine production; APOE4 impairs Aβ clearance
- TREM2 variants and microglial dysfunction: TREM2 R47H variant increases AD risk ~3-fold; impairs microglial clustering around plaques and Aβ phagocytosisdeczkowska2021 2021, deczkowska2021schultz2024 2024, schultz2024
- Blood-brain barrier disruption: Chronic inflammation compromises BBB integrity, allowing peripheral immune cell infiltrationbloodbrain2023 2023, bloodbrain2023
| Target |
Mechanism |
Development Stage |
Clinical Trial Evidence |
| NLRP3 inhibitors |
Block inflammasome activation |
Preclinical/Phase 1 |
Reduces IL-1β in animal models |
| TREM2 agonists |
Enhance microglial phagocytosis |
Phase 2/3 |
Aporvasuren (NCT04835500) |
| Anti-IL-1β antibodies |
Neutralize IL-1β |
Phase 2 |
Mixed results; ongoing trials |
| CSF1R antagonists |
Deplete microglia |
Phase 1/2 |
PLX5622 (NCT03509012) |
| Anti-TNF therapies |
Inhibit TNF-α signaling |
Phase 2 |
Etanercept showed cognitive benefit |
¶ Regional Vulnerability and Inflammation
The substantia nigra pars compacta (SNc) exhibits particular vulnerability to inflammatory damage in PD. This vulnerability stems from multiple factorshirsch2009 2009, Neuroinflammation in Parkinson:
- High basal oxidative stress: Dopaminergic neurons have high metabolic activity and iron content, creating a pro-oxidant environment
- Mitochondrial dysfunction: Complex I deficiency in PD brains amplifies ROS production and inflammasome activation
- Neuromelanin: The pigmented neurons of SNc contain neuromelanin, which can bind iron and trigger microglial activation when released
Post-mortem studies consistently demonstrate:
- Activated microglia in the SNc and striatum
- Elevated pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in the substantia nigra and CSF
- Infiltrating T cells in the SNc of PD patients
- Upregulated NF-κB and MAPK signaling in glia
- Alpha-synuclein as trigger: Aggregated α-synuclein activates microglia via TLR2, TLR4, and CD36; extracellular α-synuclein acts as damage-associated molecular pattern (DAMP)hirsch2009 2009, Neuroinflammation in Parkinsonsukhranjan2021 2021, sukhranjan2021
- Mitochondrial inflammation: PINK1 and Parkin mutations (causing familial PD) lead to accumulation of damaged mitochondria that trigger NLRP3 inflammasome activationhoeijmakers2022 2022, hoeijmakers2022
- Gut-brain axis: Gastrointestinal inflammation precedes CNS pathology in many PD patients; alpha-synuclein aggregation begins in the enteric nervous systemgutbrain2022 2022, Gut-brain axis in Parkinsonchen2023 2023, chen2023
- Peripheral inflammation: Systemic inflammatory conditions (e.g., inflammatory bowel disease) increase PD risk; peripheral immune cells infiltrate the PD brain
- Glymphatic dysfunction: Impaired clearance of interstitial waste products in PD brain may contribute to inflammatory responses
| Target |
Mechanism |
Development Stage |
Clinical Trial Evidence |
| GLP-1 receptor agonists |
Anti-inflammatory; neuroprotective |
Phase 3 |
Lixixa (EXENATIDE) showed motor benefit |
| NLRP3 inhibitors |
Block inflammasome |
Preclinical |
Effective in PD mouse models |
| Anti-TNF therapies |
Inhibit TNF-α |
Phase 1/2 |
Infliximab trial (NCT05365095) |
| Microglial modulators |
Shift to anti-inflammatory phenotype |
Phase 1/2 |
Minocycline showed mixed results |
| CX3CR1 antagonists |
Reduce microglial recruitment |
Preclinical |
Effective in animal models |
Microglia are the resident immune cells of the CNS, originating from yolk sac progenitors during embryogenesis. They self-renew throughout life and adopt diverse phenotypes in response to environmental cuesdeczkowska2021 2021, deczkowska2021kerenshaul2017 2017, kerenshaul2017.
Functions in the healthy brain:
- Synaptic pruning during development and adulthood
- Surveillance and process motility
- Phagocytosis of cellular debris
- Support of neuronal health through trophic factor release
Dysfunction in neurodegeneration:
- Impaired Aβ and α-synuclein clearance
- Enhanced pro-inflammatory cytokine production
- Reduced neurotrophic support
- Synaptic pruning dysregulation
Astrocytes respond to CNS injury by becoming "reactive" and adopting a spectrum of phenotypes from protective to harmfulsingh2022 2022, singh2022liddelow2018 2018, liddelow2018.
Reactive astrogliosis:
- Upregulation of glial fibrillary acidic protein (GFAP)
- Proliferation and formation of glial scars
- Release of both pro-inflammatory (IL-1β, TNF-α) and anti-inflammatory (IL-10, BDNF) factors
- Disruption of the blood-brain barrier
Astrocyte dysfunction in AD/PD:
- Impaired glutamate uptake leading to excitotoxicity
- Reduced potassium buffering
- Dysregulation of water and ion homeostasis
- Failure to support neuronal metabolism
¶ Diagnostic and Prognostic Biomarkers
| Biomarker |
Change in AD |
Change in PD |
Clinical Utility |
| IL-1β |
Increased |
Increased |
Disease severity marker |
| TNF-α |
Increased |
Increased |
Prognostic indicator |
| IL-6 |
Increased |
Increased |
Cognitive decline predictor |
| NFL |
Increased |
Increased |
Disease progression marker |
| YKL-40 |
Increased |
Increased |
Microglial activation marker |
| sTREM2 |
Increased |
Variable |
Disease stage indicator |
Recent advances in ultrasensitive detection methods (Simoa, Single Molecule Array) have enabled detection of inflammatory markers in blood:
- IL-6: Elevated in AD; correlates with cognitive decline
- TNF-α: Elevated in both AD and PD
- NfL (Neurofilament Light Chain): Marker of neuroaxonal damage; predicts progression
- GFAP: Astrocyte activation marker; elevated in AD
Both AD and PD share several key inflammatory mechanisms:
- NLRP3 inflammasome activation: Triggered by Aβ, α-synuclein, and mitochondrial DAMPs; leads to caspase-1 activation and cytokine maturation
- Microglial dysregulation: Both diseases feature chronic microglial activation with impaired clearance functions
- Blood-brain barrier breakdown: Peripheral immune cell infiltration in both conditions
- Peripheral inflammation: Systemic inflammatory conditions increase risk for both AD and PD
- Genetic overlap: APOE, TREM2, and CD33 variants influence risk for both diseases
| Disease Stage |
AD |
PD |
| Preclinical |
Microglial activation detectable before plaques |
Enteric nervous system inflammation |
| Prodromal |
Elevated CSF inflammatory markers |
REM sleep behavior disorder (RBD) |
| Clinical |
Prominent neuroinflammation correlates with cognitive decline |
Motor symptoms with nigral inflammation |
Microglial targeting:
- TREM2 agonists to enhance phagocytosis
- CSF1R antagonists to deplete/reprogram microglia
- CX3CR1 agonists to restore neuron-microglia communication
- NLRP3 inflammasome inhibitors
Cytokine targeting:
- Anti-IL-1β antibodies (Canakinumab)
- Anti-TNF therapies (Etanercept, Infliximab)
- IL-6 receptor antagonists (Tocilizumab)
Cell-based therapies:
- Mesenchymal stem cells (MSC) with immunomodulatory properties
- Regulatory T cell (Treg) therapy
- Myeloid-derived suppressor cells (MDSC)
- Reduction of inflammatory triggers: Aβ and α-synuclein vaccination/antibodies
- Antioxidant therapy: N-acetylcysteine, CoQ10, vitamin E
- Metabolic support: Ketogenic diets, glucose metabolism modulators
- Lifestyle interventions: Exercise, diet, sleep optimization
¶ Research Directions and Future Perspectives
- Single-cell multi-omics: Integration of transcriptomics, epigenomics, and proteomics to understand glial heterogeneity
- Brain-immune interface: Mapping the glymphatic system and meningeal lymphatics
- Microglial reprogramming: Converting disease-associated microglia to a homeostatic phenotype
- Peripheral-central immune crosstalk: Understanding how peripheral immunity influences CNS inflammation
- Spatial transcriptomics: Mapping inflammatory responses at tissue level
¶ Challenges and Opportunities
Challenges:
- Lack of validated anti-inflammatory therapies in large clinical trialstracey2022 2022, tracey2022
- Complexity of microglial phenotypes and context-dependent functions
- Difficulty translating mouse model findings to human disease
- Blood-brain barrier limits drug delivery to CNS
Opportunities:
- Genetic insights from GWAS identifying novel inflammatory targets
- Advances in human iPSC-derived glial models
- Biomarker development for patient stratificationcsf2024 2024, csf2024
- Combination therapies targeting multiple inflammatory pathways
flowchart TD
subgraph Triggers["Triggers"]
A["Amyloid-β Plaques"]
B["Tau Pathology"]
Cα-Synuclein["Cα-Synuclein Aggregation"]
D["Genetic Risk Factors"]
E["Mitochondrial Dysfunction"]
end
subgraph GlialActivation["Glial Cell Activation"]
F["Microglia Activation"]
G["Astrocyte Activation"]
end
subgraph Mediators["Inflammatory Mediators"]
H["Pro-inflammatory Cytokines"]
H1["IL-1β"]
H2["IL-6"]
H3["TNF-α"]
H4["IL-18"]
I["Chemokines"]
I1["CCL2/MCP-1"]
I2["CX3CL1/Fractalkine"]
I3["CXCL10"]
end
subgraph Pathways["Signaling Pathways"]
J["NF-κB Pathway"]
K["MAPK Pathways"]
L["NLRP3 Inflammasome"]
M["TREM2 Signaling"]
end
subgraph Effects["Cellular Effects"]
N["Synaptic Loss"]
O["Neuronal Death"]
P["Oxidative Stress"]
Q["BBB Breakdown"]
end
subgraph Diseases["Disease Outcomes"]
R["Alzheimer's Disease"]
S["Parkinson's Disease"]
end
A --> F
B --> F
C --> F
D --> F
E --> F
A --> G
B --> G
F --> H
G --> H
H --> H1
H --> H2
H --> H3
H --> H4
F --> I
I --> I1
I --> I2
I --> I3
H --> J
H --> K
H --> L
F --> M
J --> N
K --> N
L --> O
J --> O
K --> O
H --> P
L --> P
H --> Q
N --> R
O --> R
Q --> R
N --> S
O --> S
P --> S
style A fill:#f3e5f5,stroke:#333
style B fill:#f3e5f5,stroke:#333
style C fill:#f3e5f5,stroke:#333
style R fill:#fff9c4,stroke:#333
style S fill:#fff9c4,stroke:#333
style O fill:#fff3e0,stroke:#333
Neuroinflammation represents a central pathological mechanism in both Alzheimer's and Parkinson's disease, acting not merely as a secondary consequence of protein aggregation but as an active driver of neurodegeneration. The complex interplay between glia, neurons, and peripheral immune systems creates self-perpetuating inflammatory cycles that accelerate disease progression.
Understanding the temporal and spatial dynamics of neuroinflammation, identifying valid therapeutic targets, and developing effective anti-inflammatory therapies remain critical priorities for disease modification in AD and PD. The convergence of genetic, transcriptomic, and clinical data offers unprecedented opportunities to translate mechanistic insights into clinical benefits for patients.
Transgenic mouse models have been instrumental in understanding neuroinflammatory mechanisms in AD and PD. The 5xFAD model (APP/Sw/LO family with 5 familial AD mutations) demonstrates robust amyloid deposition and associated microglial activation starting at 2-3 months of age. The MAPT P301S tauopathy model shows progressive tau pathology with microglial activation and motor deficits.
For PD, the α-synuclein overexpression models (e.g., Thy1-αSyn) develop progressive motor dysfunction and α-synuclein aggregation. MitoPark mice (conditional deletion of mitochondrial complex I in dopaminergic neurons) model PD-related mitochondrial dysfunction and neuroinflammation.
- Microglial depletion studies: PLX5622 (CSF1R antagonist)-mediated microglial depletion reduces Aβ burden but impairs synaptic function, demonstrating the complex role of microgliacheng2024 2024, cheng2024
- TREM2 activation: Anti-TREM2 antibodies enhance microglial clustering around plaques and reduce synaptic loss in 5xFAD miceschultz2024 2024, schultz2024
- NLRP3 inhibition: MCC950 (NLRP3 inhibitor) reduces neuroinflammation and improves behavioral outcomes in both AD and PD mouse modelsoliver2022 2022, oliver2022
- α-Synuclein propagation: Microglia phagocytose and spread α-synuclein between brain regions via tunneling nanotubessong2023 2023, song2023
- Microglial repopulation: After depletion, new microglia can repopulate the brain with a more homeostatic phenotypesong2023 2023, song2023
- Species differences in microglial biology and brain structure
- Artificial overexpression systems vs. endogenous protein dynamics
- Limited reproduction of human-specific aging processes
- Lack of complete replicates of human neuropathology
¶ Completed and Ongoing Trials
| Trial |
Intervention |
Target |
Phase |
Status |
| NCT02547801 |
Etanercept |
TNF-α |
Phase 2 |
Completed |
| NCT03091478 |
Canakinumab |
IL-1β |
Phase 2 |
Completed |
| NCT04835500 |
Aporvasuren |
TREM2 |
Phase 2 |
Ongoing |
| NCT05365095 |
Infliximab |
TNF-α |
Phase 1 |
Recruiting |
| NCT04547504 |
LY3471851 (NKTR-102) |
IL-6 |
Phase 2 |
Completed |
- Timing matters: Anti-inflammatory interventions may be most effective in early/prodromal disease stages
- Target validation: Genetic evidence (TREM2, NLRP3) provides strong rationale for target engagement
- Biomarker-driven trials: Patient selection based on inflammatory biomarker profiles may improve outcomes
- Peripheral vs. central: Targeting peripheral inflammation may be safer than CNS-directed approaches
- TREM2: Variant R47H increases AD risk ~3-fold; impairs microglial phagocytosis
- CD33: Sialic acid-binding Ig-like lectin; regulates microglial activation
- APOE: APOE4 carriers show enhanced neuroinflammation and impaired Aβ clearance
- CLU (Clusterin): Involved in complement regulation and Aβ clearance
- CR1 (Complement receptor 1): Regulates complement-mediated inflammation
- GBA: Glucocerebrosidase mutations increase PD risk; affect lysosomal function and α-synuclein aggregation
- LRRK2: Leucine-rich repeat kinase 2; regulates inflammatory responses in microglia
- SNCA: α-Synuclein; activates microglia via pattern recognition receptors
- PINK1/Parkin: Mitochondrial quality control; mutations cause familial PD with inflammasome activation
- Whole-genome sequencing to identify rare variants
- Expression quantitative trait loci (eQTL) mapping in microglia
- Polygenic risk scores incorporating inflammatory pathways